https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-01 / J. Immunother. 2008 Jun;31(5):458-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-01 / J. Immunother. 2008 Jun;31(5):458-652008-06-01 00:00:002019-02-15 09:19:27Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-92008-05-15 00:00:002019-02-15 09:19:21Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):345-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):345-582008-05-01 00:00:002019-02-15 09:19:30Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):402-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):402-122008-05-01 00:00:002019-02-15 09:19:31Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-92008-04-24 00:00:002019-02-15 08:49:58Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:28-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:28-422008-04-01 00:00:002019-02-15 09:19:33Strategies and challenges in eliciting immunity to melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Cancer Biother. Radiopharm. 2008 Apr;23(2):214-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Cancer Biother. Radiopharm. 2008 Apr;23(2):214-212008-04-01 00:00:002019-02-15 09:19:30Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Immunol. Rev. 2008 Apr;222:242-552008-04-01 00:00:002019-02-15 09:19:32Cancer vaccines for established cancer: how to make them better?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-26 / J. Cancer Res. Clin. Oncol. 2008 Sep;134(9):987-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-26 / J. Cancer Res. Clin. Oncol. 2008 Sep;134(9):987-942008-02-26 00:00:002019-02-15 09:19:23Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-342008-02-08 00:00:002019-02-15 08:49:32Dendritic cell vaccines in melanoma: from promise to proof?
